omeprazole has been researched along with Disbacteriosis in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole treatment inhibits gastric acidity, rescuing morphine-induced gastric dysbiosis and preventing inflammation." | 5.91 | Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition. ( Chupikova, I; Ghosh, N; Kesh, K; Ramakrishnan, S; Roy, S; Sharma, U; Singh, PK, 2023) |
| "Omeprazole treatment inhibits gastric acidity, rescuing morphine-induced gastric dysbiosis and preventing inflammation." | 1.91 | Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition. ( Chupikova, I; Ghosh, N; Kesh, K; Ramakrishnan, S; Roy, S; Sharma, U; Singh, PK, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ghosh, N | 1 |
| Kesh, K | 1 |
| Singh, PK | 1 |
| Sharma, U | 1 |
| Chupikova, I | 1 |
| Ramakrishnan, S | 1 |
| Roy, S | 1 |
| Zhou, Y | 1 |
| Ye, Z | 1 |
| Lu, J | 1 |
| Miao, S | 1 |
| Lu, X | 1 |
| Sun, H | 1 |
| Wu, J | 1 |
| Wang, Y | 1 |
| Huang, Y | 1 |
| Bajaj, JS | 1 |
| Liu, EJ | 1 |
| Kheradman, R | 1 |
| Fagan, A | 1 |
| Heuman, DM | 1 |
| White, M | 1 |
| Gavis, EA | 1 |
| Hylemon, P | 1 |
| Sikaroodi, M | 1 |
| Gillevet, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01458990] | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Analysis at baseline will be compared to that at 2 weeks. This will be specifically, changes in those with PPI withdrawal compared to those with PPI initiation (NCT01458990)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| PPI Initiation | 0 |
| PPI Withdrawal | 0 |
Analysis at baseline will be compared to that at 2 weeks using Multitagged sequencing. Number of patients with overgrowth of oral microbiota in their stool after PPI therapy withdrawal or initiation were specifically analyzed. (NCT01458990)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| PPI Inititation | 45 |
| PPI Withdrawal | 15 |
1 trial available for omeprazole and Disbacteriosis
| Article | Year |
|---|---|
Fungal dysbiosis in cirrhosis.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Cross-Sectional Studies; Dysbiosis; Female; Follow-Up Studie | 2018 |
2 other studies available for omeprazole and Disbacteriosis
| Article | Year |
|---|---|
Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition.
Topics: Analgesics, Opioid; Animals; Dysbiosis; Inflammation; Mice; Morphine; Omeprazole; Proton Pump Inhibi | 2023 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hyp | 2020 |